Biomaterial-engineered intra-articular drug delivery systems for osteoarthritis therapy

Drug Delivery

Longfa Kou¹  Ruijie Chen¹  Shihui Bao¹  Rui Sun¹  Shuyi Xiao¹  Qing Yao² 

[1] The Second Affiliated Hospital and Yuying Children’s Hospital of Wenzhou Medical University;Wenzhou Medical University;

关键词: drug delivery system;    osteoarthritis;    nanomedicine;    retention time;    delayed release;   

DOI  :  10.1080/10717544.2019.1660434

来源: DOAJ

【 摘 要 】

Osteoarthritis (OA) is a progressive and degenerative disease, which is no longer confined to the elderly. So far, current treatments are limited to symptom relief, and no valid OA disease-modifying drugs are available. Additionally, OA relative joint is challenging for drug delivery, since the drugs experience rapid clearance in joint, showing a poor bioavailability. Existing therapeutic drugs, like non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids, are not conducive for long-term use due to adverse effects. Though supplementations, including chondroitin sulfate and glucosamine, have shown beneficial effects on joint tissues in OA, their therapeutic use is still debatable. New emerging agents, like Kartogenin (KGN) and Interleukin-1 receptor antagonist (IL-1 ra), without a proper formulation, still will not work. Therefore, it is urgent to establish a suitable and efficient drug delivery system for OA therapy. In this review, we pay attention to various types of drug delivery systems and potential therapeutic drugs that may escalate OA treatments.

【 授权许可】

Unknown